Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

ID
Name
DSPCLAT-001
Description
It's a prospective, non-interventional, observational Post-marketing Surveillance..
Trial arms
Trial start
2020-12-01
Estimated PCD
2023-03-18
Trial end
2023-06-18
Status
Completed
Treatment
Lurasidone HCl
This is a non-interventional, observational study
Arms:
Latuda®
Other names:
Latuda®
Size
3192
Primary endpoint
The incidence of Adverse Event
week 12
Eligibility criteria
Inclusion Criteria: * Schizophrenia Patients who begin to receive Latuda® Exclusion criteria: * No exclusion criteria
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '12 Weeks', 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 3192, 'type': 'ACTUAL'}}
Updated at
2024-04-18

1 organization

1 product

1 indication

Product
Lurasidone
Indication
Schizophrenia
Organization
Sumitomo Pharma